4.8 Article

Influence of graft composition in patients with hematological malignancies undergoing ATG-based haploidentical stem cell transplantation

Journal

FRONTIERS IN IMMUNOLOGY
Volume 13, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2022.993419

Keywords

haploidentical hematopoietic stem cell transplantation; graft composition; G-CSF-mobilized BM cells; G-CSF-mobilized PBSCs; total nucleated cells

Categories

Funding

  1. National Natural Science Foundation of China [81974003, 81900181, 81370668]
  2. Key Scientific Research Project of Henan University [20A320021]
  3. Joint Co-construction Project of Henan Medical Technology Research Plan [2018020028]
  4. Key Science and Technology Project of Henan Province [SBGJ202103054]
  5. Natural Science Foundation of Hubei Province [2020CFB772, 2020CFB790]
  6. Collaborative Innovation Center of Hematology of China

Ask authors/readers for more resources

This study examined the influence of graft composition in haploidentical hematopoietic stem cell transplantation. The results showed that using G-CSF-primed bone marrow and peripheral blood stem cells had comparable outcomes to using only G-CSF-mobilized peripheral blood stem cells. Furthermore, patients with a certain range of nucleated cell transfusion had lower transplant-related mortality and slightly improved survival rates. These findings suggest that adjusting the composition and ratio of graft cells can enhance the efficacy of haploidentical hematopoietic stem cell transplantation.
To determine the influence of graft composition in haplo-HSCT, we summarized the long-term consequences of 251 consecutive transplantations from haploidentical donors. For donor-recipient HLA3/6-matched setting, 125 cases used G-CSF-mobilized BM and PBSCs mixtures, while 126 cases only used G-CSF-mobilized PBSCs in HLA4/6-matched transplantation. On the one hand, we wanted to explore the effect of harvests (CD34+ cells and TNCs dosages) on transplantation outcome in the context of haplo-HSCT no matter HLA4/6 or HLA3/6-matched setting. On the other hand, for patients using G-CSF-mobilized BM and PBSCs combination in HLA3/6-matched setting, we attempted to analyze whether TNCs or CD34+ cells from G-CSF-mobilized BM or G-CSF-mobilized PBSCs play the most paramount role on transplantation prognosis. Collectively, patients with hematologic malignancies receiving G-CSF-primed BM and PBSCs harvests had comparable consequences with patients only receiving G-CSF-mobilized PBSCs. Moreover, when divided all patients averagely according to the total amount of transfused nucleated cells, 3-year TRM of the intermediate group (13.06-18.05x10(8)/kg) was only 4.9%, which was remarkably reduced when compared to lower and higher groups with corresponding values 18.3%, 19.6% (P=0.026). The 3-year probabilities of OS and DFS of this intermediate group were 72.6% and 66.5%, which were slightly improved than the lower and higher groups. Most importantly, these data suggest that the transfused nucleated cells from G-CSF-primed BM above than 5.20x10(8)/kg could achieve remarkably lower TRM in haplo-HSCT receiving G-CSF-mobilized BM and PBSCs harvests. These encouraging results suggested that we could improve the efficacy of haplo-HSCT by adjusting the component and relative ratio of transfused graft cells. Nevertheless, the above findings should be confirmed in a randomized prospective comparative research with adequate follow-up.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available